Biotech stocks are booming again.

The iShares Nasdaq Biotechnology ETF (IBB) - Get Report closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25. The sector's steep sell off in March and April are a distant memory. Roche's (RHHBY) acquisition of InterMune (ITMN) has put some M&A oomph into biotech stocks.




As you'd expect, biotech stocks are out-performing the S&P 500.

Image placeholder title




The S&P Biotech ETF (XBI) - Get Report is also showing a strong recovery but not as much as the IBB given the former's broader exposure to small-cap stocks.

Image placeholder title
Image placeholder title

Gilead Sciences (GILD) - Get Report leads the biotech big caps by a wide margin:

Image placeholder title

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.